🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. KP415 oral capsule

    ZEVRA THERAPEUTICS, INC.

    ADHD

    phase 3 small molecule completed

    2 trials

  2. KYV-101

    Kyverna Therapeutics

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial

  3. Kamada-AAT for Inhalation, Placebo for “Kamada-AAT for Inhalation”

    Kamada BioPharma Limited at Fieldfisher LLP

    Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year.

    phase 3 small molecule active

    1 trial

  4. Kerendia 10 mg film coated tablets, Placebo coated tablet 002 to bay 948862 coated tablet, Kerendia 20 mg film-coated tablets

    The George Institute

    Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  5. Ketamine

    United Therapeutics Europe Ltd

    Chronic Pain

    phase 3 small molecule completed

    1 trial

  6. Ketamine Hydrochloride

    United Therapeutics Europe Ltd

    Traumatic Injury

    phase 3 small molecule active

    1 trial

  7. Ketamine Hydrochloride

    Camp4 Therapeutics Corp

    Suicide

    phase 3 small molecule terminated

    1 trial

  8. Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml

    Disc Medicine

    Non-psychotic therapy resistant unipolar depression

    phase 3 small molecule active

    1 trial

  9. Ketorolac

    The First People's Hospital of Lianyungang

    Aortic Dissection

    phase 3 small molecule active

    1 trial

  10. Keverprazan Hydrochloride tablets + high dose amoxicillin

    The First People's Hospital of Lianyungang

    Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education

    phase 3 small molecule active

    1 trial

  11. Khalas dates

    United Therapeutics Europe Ltd

    Diabetes Mellitus

    phase 3 other completed

    1 trial

  12. L-leucovorin

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  13. LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR

    Orchard Therapeutics (Netherlands) B.V.

    Mucopolysaccharidosis type I, Hurler Syndrome

    phase 3 small molecule active

    1 trial

  14. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  15. LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT

    Stemline Therapeutics B.V.

    Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

    phase 3 small molecule active

    1 trial

  16. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  17. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  18. LI

    Teva Pharma GmbH

    Squamous Cell Carcinoma of the Oral Cavity

    phase 3 mab completed

    1 trial

  19. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  20. LIOTHYRONINE SODIUM , LEVOTHYROXINE SODIUM , Placebo tablets are white, round, biconvex tablets. The tablets contain no active pharmaceutical ingredient (API), but are manufactured following the manufacturing process of the liothyronine tablets presented in the IMPD for liotyronine 2, 2.5, 3.75, and 5 µg

    Disc Medicine

    Hypothyroidism Triiodothyronine Quality of Life Persistant complaints

    phase 3 small molecule active

    1 trial

  21. LY2127399

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  22. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  23. Lactobacillus plantarum

    United Therapeutics Europe Ltd

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  24. Lactobacillus plantarum IS-10506

    United Therapeutics Europe Ltd

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources